United States Biotechnology & Medical Research

BlossomHill Therapeutics Inc (BLSM)

Track

BlossomHill Therapeutics witnessed five insider trading transactions over the past ninety days, all representing purchases. Four distinct individuals acquired shares, totaling 5.18 million dollars in net value. These acquisitions occurred despite stagnant stock performance, with no recent earnings report available to provide additional context regarding these significant capital deployments by corporate leadership.
Ticker: BLSM Exchange: NAQ
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for BlossomHill Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
1.5
GORDON CARL L Non-Executive Director
Transaction date
Purchase
Price
42.28
Quantity 81,277 -9.4%
Value US$4,789,125
2.6
ORBIMED ADVISORS LLC Non-Executive Director
Transaction date
Purchase
Price
499.38
Quantity 14,003 +44.1%
Value US$1,699,899
1.9
Schmid John P. Non-Executive Director
Transaction date
Purchase
Price
295.15
Quantity 6,885 -25.8%
Value US$136,511
2.2
Chen Bihua Non-Executive Director Large shareholder
Transaction date
Purchase
Price
16.00
Quantity 1,000 +9.5%
Value US$100,000
Keyes Jason A Chief Financial Officer Officer
Transaction date
Purchase
Price
16.00
Quantity 1,000 +inf%
Value US$100,000
Liptak Vincent Paul General Counsel Officer
Transaction date
Purchase
Price
16.00
Quantity 1,000 +2.0%
Value US$100,000
Liptak Vincent Paul General Counsel Officer
Transaction date
Purchase
Price
15.80
Quantity 1,000 +2.3%
Value US$100,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-12 2026-08-10 B Purchase
1.5
GORDON CARL L
Non-Executive Director
81,277 -9.4%
42.28
US$4,789,125 		81,277 -9.4% 42.28 US$4,789,125
2026-08-12 2026-08-10 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director
14,003 +44.1%
499.38
US$1,699,899 		14,003 +44.1% 499.38 US$1,699,899
2026-08-10 2026-08-10 B Purchase
1.9
Schmid John P.
Non-Executive Director
6,885 -25.8%
295.15
US$136,511 		6,885 -25.8% 295.15 US$136,511
2026-08-10 2026-08-10 B Purchase
2.2
Chen Bihua
Non-Executive Director Large shareholder
1,000 +9.5%
16.00
US$100,000 		1,000 +9.5% 16.00 US$100,000
2026-08-10 2026-08-10 B Purchase
Keyes Jason A

Chief Financial Officer

Officer
1,000 +inf%
16.00
US$100,000 		1,000 +inf% 16.00 US$100,000
2026-08-10 2026-08-10 B Purchase
Liptak Vincent Paul

General Counsel

Officer
1,000 +2.0%
16.00
US$100,000 		1,000 +2.0% 16.00 US$100,000
2026-08-10 2026-08-07 B Purchase
Liptak Vincent Paul

General Counsel

Officer
1,000 +2.3%
15.80
US$100,000 		1,000 +2.3% 15.80 US$100,000
Explore more

More insider trading research around BlossomHill Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America